Table 3.

Lipid parameters of controls, bi-RTI, PI+LD−, and PI+LD+ patients

Parameters HIV− Controls, n = 12Bi-RTI, n = 10 PI+LD−, n = 13 PI+LD+, n = 17
Cholesterol, mmol/L (g/L)  4.8 ± 0.9 4.4 ± 1.2  5.0 ± 1.3  6.9 ± 0.173-152 
 (1.85 ± 0.34)  (1.70 ± 0.46)  (1.94 ± 0.51) (2.68 ± 0.653-152)  
HDL cholesterol, mmol/L (g/L) 1.3 ± 0.18  0.54 ± 0.133-150 1.6 ± 0.853-151 1.2 ± 0.443-151 
 (0.52 ± 0.07)  (0.21 ± 0.053-150) (0.62 ± 0.333-151)  (0.46 ± 0.173-151)  
Triglycerides, mmol/L (g/L)  1.06 ± 0.42  2.2 ± 2.03-150 2.2 ± 0.5 4.6 ± 4.43-152 
 (0.94 ± 0.37)  (1.99 ± 1.753-150) (1.09 ± 0.44)  (4.13 ± 3.923-152)  
ApoB, g/L 0.85 ± 0.20  1.08 ± 0.17  0.75 ± 0.23 1.57 ± 0.363-152 
ApoB/apoA1 ratio  0.54 ± 0.12 0.54 ± 0.11  0.72 ± 0.24  1.15 ± 0.343-152 
Parameters HIV− Controls, n = 12Bi-RTI, n = 10 PI+LD−, n = 13 PI+LD+, n = 17
Cholesterol, mmol/L (g/L)  4.8 ± 0.9 4.4 ± 1.2  5.0 ± 1.3  6.9 ± 0.173-152 
 (1.85 ± 0.34)  (1.70 ± 0.46)  (1.94 ± 0.51) (2.68 ± 0.653-152)  
HDL cholesterol, mmol/L (g/L) 1.3 ± 0.18  0.54 ± 0.133-150 1.6 ± 0.853-151 1.2 ± 0.443-151 
 (0.52 ± 0.07)  (0.21 ± 0.053-150) (0.62 ± 0.333-151)  (0.46 ± 0.173-151)  
Triglycerides, mmol/L (g/L)  1.06 ± 0.42  2.2 ± 2.03-150 2.2 ± 0.5 4.6 ± 4.43-152 
 (0.94 ± 0.37)  (1.99 ± 1.753-150) (1.09 ± 0.44)  (4.13 ± 3.923-152)  
ApoB, g/L 0.85 ± 0.20  1.08 ± 0.17  0.75 ± 0.23 1.57 ± 0.363-152 
ApoB/apoA1 ratio  0.54 ± 0.12 0.54 ± 0.11  0.72 ± 0.24  1.15 ± 0.343-152 

Drug regimens are detailed in the notes of Table 2. Values are given as the mean plus or minus SD.

F3-150

P < .05 vs HIV− control group.

F3-151

P < .05 vs bi-RTI group.

F3-152

P < .05 vs HIV− control, bi-RTI, and PI+LD− groups.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal